22876-17-1

Usage

Uses

Used in Scientific Research:
6-AMINO-1,3-BENZOXAZOL-2(3H)-ONE is used as a research compound for its reactivity and specificity in various chemical and biochemical reactions. It is particularly valuable in the synthesis of microbial secondary metabolites, where it serves as a hypothesized intermediate.
Used in Chemical Synthesis:
6-AMINO-1,3-BENZOXAZOL-2(3H)-ONE is used as a synthetic intermediate for the production of various compounds. Its reactivity under different conditions allows for the creation of a wide range of products, making it a versatile component in chemical synthesis processes.
Used in Biochemical Reactions:
6-AMINO-1,3-BENZOXAZOL-2(3H)-ONE is used as a reactant in biochemical reactions, where its specific reactivity can be harnessed to achieve desired outcomes. Its role in these reactions is crucial for understanding and manipulating biological processes at the molecular level.

InChI:InChI=1/C7H6N2O2/c8-4-1-2-5-6(3-4)11-7(10)9-5/h1-3H,8H2,(H,9,10)

Upstream product

• 4694-91-1 6-nitro-3H-benzooxazol-2-one 
• 121-88-0 5-Nitro-2-aminophenol 
• 59-49-4 2-Benzoxazolinone 
• 38880-75-0 (2-hydroxy-4-nitro-phenyl)-carbamic acid ethyl ester 

Downstream Products

• 103391-39-5 diphenyl-acetic acid-(3-diphenylacetyl-2-oxo-2,3-dihydro-benzoxazol-6-ylamide) 
• 81110-79-4 (2-oxo-2,3-dihydro-benzoxazol-6-yl)-urea 
• 102024-56-6 N'-(2-oxo-2,3-dihydro-benzoxazol-6-yl)-N,N-diphenyl-urea 
• 99584-10-8 6-amino-3-methyl-1,3-benzoxazol-2(3H)-one 
• 496054-87-6 Radiprodil 
• 933474-45-4 2-(4-benzylpiperidin-1-yl)-N-(5-nitro-2-oxo-2,3-dihydro-benzoxazol-6-yl)-2-oxo-acetamide 
• 933474-46-5 N-(5-amino-2-oxo-2,3-dihydro-benzoxazol-6-yl)-2-(4-benzylpiperidin-1-yl)-2-oxo-acetamide 
• 1061355-05-2 N-methyl-2-(2-(2-oxo-2,3-dihydrobenzo[d]oxazol-6-ylamino)-5-(trifluoromethyl)pyridin-4-ylamino)benzamide trifluoroacetate 
• 948022-28-4 C₁₉H₁₉ClN₄O₃ 
• 948020-54-0 C₂₀H₁₈F₃N₃O₃ 
• 948020-43-7 C₂₂H₂₂F₃N₃O₃ 
• 948020-44-8 C₂₁H₂₀F₃N₃O₃ 
• 948020-52-8 C₂₁H₁₈F₃N₃O₃ 
• 948020-62-0 C₂₁H₁₈F₃N₃O₄ 

Relevant academic research and scientific papers

NOVEL HYDRAZONE DERIVATIVE WITH ARYL OR HETEROARYL GROUP SUBSTITUTED AT TERMINAL AMINE GROUP THEREOF AND USE THEREOF

The present invention relates to novel hydrazone derivatives in which a terminal amine group is substituted with an aryl group or a heteroaryl group, and uses thereof.

Novel hydrazone derivatives comprising aryl or heteroaryl group substituted at terminal amine and use thereof

The present invention relates to novel hydrazone derivatives with an aryl or heteroaryl group substituted at a terminal amine group thereof and a use thereof.

Replacement of the Benzylpiperidine Moiety with Fluorinated Phenylalkyl Side Chains for the Development of GluN2B Receptor Ligands

The 4-benzylpiperidine moiety is a central structural element of potent N-methyl-d-aspartate (NMDA) receptor antagonists containing the GluN2B subunit. To obtain novel GluN2B ligands suitable for positron emission tomography, the benzylpiperidine moiety was replaced with fluorinated ω-phenylalkylamino groups. For this purpose three primary propyl- and butylamines 7 a–c and one butyraldehyde 7 d bearing a fluorine atom and an ω-phenyl moiety were prepared in 3- to 7-step syntheses. Compounds 7 a–d were attached to various scaffolds of potent GluN2B antagonists (scaffold hopping) instead of the original 4-benzylpiperidine moiety. Although benzoxazol-2-ones and indoles with a benzylpiperidine moiety show high GluN2B affinity, the corresponding fluorophenylalkylamine derivatives did not result in high Glu2B affinity. Moderate GluN2B affinity was observed for a 3-(fluoroalkyl)-substituted tetrahydro-1H-3-benzazepine (Ki=239 nm). However, high GluN2B affinity was obtained for the tetrahydro-5H-benzo[7]annulen-7-amines 12 a–c (Ki=17–30 nm). Docking studies resulted in the same binding pose for 12 a as for the lead compound Ro 25-6981. It can be concluded that some GluN2B ligands (benzoxazolones, indoles) do not tolerate replacement of the 4-benzylpiperidine moiety with flexible fluorinated phenylalkyl side chains, but other scaffolds such as tetrahydro-3-benzazepines and -benzo[7]annulenes retain interaction with NMDA receptors containing the GluN2B subunit.

Novel Compounds as Autotaxin Inhibitors and Pharmaceutical Compositions Comprising the Same

The present invention relates to a novel autotaxin inhibitor compound for preventing and treating disease or symptoms due to an increase in concentration of lysophosphatidic acid or activation of autotaxin. The present invention further relates to a pharmaceutical composition containing the same. The novel compound of the present invention is an autotaxin inhibitor which inhibits production of lysophosphatidic acid, and thus is useful for treating or preventing cardiovascular disease, cancer, metabolic disease, kidney disease, liver disease, inflammatory diseases, nervous disease, respiratory disease, desmoid disease, eye disease, cholestatic symptoms, other types of chronic pruritus or acute, or chronic rejection of transplanted organs.COPYRIGHT KIPO 2017

Comparative study of conventional and microwave-assisted synthesis of novel 6-(arylideneamino)benzo[d]oxazol-2(3H)-ones with potential antibacterial activity

(Formula presented) The synthesis and characterization of novel class of Schiff bases derivatives 6-(Benzylideneamino)benzo[d]oxazol-2(3H)-ones (5a-d and 6a-d), derived from the condensation reactions of different aromatic aldehydes with 6-amino-2(3H)-benzoxazolone and 3-methyl-6-amino-2(3H)-benzoxazolone, using conventional and microwave irradiation methods was described. The structure of all newly synthesized compounds has been proven by using various spectral methods such as IR, 1H-NMR and 13C-NMR. The results confirmed that benzoxazolinonic amino group reacted with aromatic aldehydes to form the desired Schiff bases.

Experimental and theoretical investigation of the intramolecular cyclisation of N-(benzoxazolinon-6-Yl) Maleimide derivatives

A new N-H and N-CH3 2(3H)-benzoxazolones substituted at the C6 position in the aromatic ring by imide group (maleimides) has been synthesized in good yields. The regioselectivity of the cyclisation step has been investigated through DFT calculations at the B3LYP/6-31G (d,p) level of theory. The obtained results indicate that the maleimide is favored both kinetically and thermodynamically as observed experimentally.

Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents

The present invention is directed to inhibitors of S-nitrosoglutathione reductase (GSNOR), pharmaceutical compositions comprising such GSNOR inhibitors, and methods of making and using the same.

AUTOTAXIN INHIBITORS

The present invention relates to compounds according to formula (I) as autotaxin inhibitors and the use of such compounds for the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propaga

NIROGENOUS HETEROCYCLIC DERIVATIVES SUBSTITUTED WITH CYCLIC GROUPS

It was found out that the nitrogen-containing heterocyclic derivative represented by the formula (I) specifically binds to a receptor of NR1/NR2B, and is used as a NR2B receptor antagonist. A compound represented by: wherein Z is N or CR1, A1 is a nitrogen-containing aromatic monocyclic group which is optionally substituted, a nitrogen-containing aromatic fused cyclic group which is optionally substituted etc., A2 is an aromatic hydrocarbon cyclic group or an aromatic heterocyclic group, each optionally having a substituent, R1, R2, Ra, Rb, Rc and Rd are each independently hydrogen, hydroxy, etc., w is 2 or 3, t is 1 or 2, X is -(CR3R4)m-, -CO(CR3R4)n-, -CONR5(CR3R4)n- etc., m is an integer of 1 to 4, n is an integer of 0 to 4, R3 and R4 are each independently hydrogen, halogen, hydroxy etc., and R5 is hydrogen or lower alkyl, or a pharmaceutically acceptable salt, or a solvate thereof.

QUINAZOLINONE AND FUSED PYRIMIDINONE COMPOUNDS AND THEIR USE IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS

This invention is directed to compounds of formula (I): wherein (A), n, R1, R2 and R3 are as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.